Hereditary Spastic Paraplegia
(HSP)
Definition:
is a group of inherited diseases whose
main feature is progressive stiffness
and contraction (spasticity) in the lower
limbs , as a result of damage to or
dysfunction of the nerves.
1-10 in 100,000 people worldwide
have HSP
 Can affect people of all ages
, but average age at onset is 24
1
2
3
4

• Hereditary spastic paresis
• Familial spastic paraplegia
• Strumpell-Lorrain disease:
first described 1883-1888
• French Settlement
Based on
symptoms

Pure
HSP





Affects the legs only
More common
Bladder symptoms may
occur eg “urgency”

Complicated
HSP

 Spastic paraplegia with a

variety of other problems
 Other neurological problems
eg ataxia (poor balance)
Intellectual disability , dementia,
extrapyramidal signs,Seizures
Complicated HSP

Pure HSP
Based on
mode of
inheritance

Autosomal
dominant

Autosomal
recessive

X-linked
recessive
manner
Based on
patient's age
at onset

Type I
<35 years

Type II
>35 years

Spasticity>>weakness muscle weakness
urinary symptoms
sensory loss

spasticity
Based on associated gene
(Genetics)
 Neuronal degeneration
mutations at specific
genes
 Genetic mapping has identified at least 52 different
HSP loci, designated SPG 1 through 52
 Different genetic types of HSP usually cannot be
distinguished by clinical and neuroimaging parameters
alone
SPG1 (Spastic Paraplegia 1)
 Masa syndrome
Gareis-Mason syndrome
Crash syndrome
 Mutation in Gene >>>>> L1 or L1CAM protein
 Transmembrane protein >>>> neurite outgrowth
guidance, neuronal cell migration and survival
 Locus = Xq28 X-Linked
SPG2
 Mutation in Gene >>>>> Proteolipid protein
1(PLP1)
 Transmembrane protein >>>> leukodystrophy
and dysmyelination, resulting in axonal
degeneration
 Locus = Xq22 X-Linked
SPG4
 Mutation in Gene SPAST >>>>> Spastin protein
 Microtubule-severing protein >>> membrane
trafficking, intracellular motility, organelle
biogenesis, protein folding, and proteolysis
 Locus = 2p22–p21 Autosomal dominant
SPG15
 Kjellin syndrome
 Mutation in Gene >>>>> ZFYVE26
 progressive stiffness and increased reflexes
in the leg muscles as well as
retinal degeneration
 Locus =14q24.1 Autosomal recessive
SPG17
 Silver syndrome
 Mutation in Gene BSCL2 >>>>> Seipin protein
 Phenotype overlapping with distal spinal
muscular atrophy type VA
 Locus = 11q13 Autosomal dominant
SPG18
 Mutation in Gene >>>>> Erlin-2
 Characterised by joint contractures
and intellectual disability
 Locus = 8p11.23 Autosomalrecessive
Neuropathology
.
Neuropathology cont….
In Neuron Level

Axonal
Degeneration

• Lesser
Extent
Clinical Features
 Symptoms depend on the type of HSP inherited
 Main feature >>> progressive spasticity in the
lower limbs, due to pyramidal tract dysfunction
 In the lower extremities, spasticity is increased at
the hamstrings, quadriceps and ankles
 Weakness is most notable at the iliopsoas , tibialis
anterior, hamstring muscles
 difficulty in walking, decreased vibratory sense at
the ankles, and paresthesia
 In lower extremities hyperreflexia, brisk
reflexes, extensor plantar reflexes
Normal reflex during walking Abnormal reflex during Gait/walking
 additional symptoms in complicated
form include:
peripheral neuropathy, amyotrophy, ata
xia, mentalretardation, ichthyosis, epile
psy,optic neuropathy, dementia, deafne
ss, or problems with
speech, swallowing or breathing
Diagnosis

Genetic
Instrumental testing
Tests
Examination
leg muscles Brain and spine
MRI
Family
feel stiff
Rule out other
history
causes
brisk reflexes
any
History
relatives
Complains affected?
eg .walking
difficulty
Genetic testing
• Diagnostic
- Person is affected with symptoms
- Wants to know the cause

• Predictive
- Person not affected with symptoms
- Has a relative eg parent with HSP
Differential Diagnosis
•
•

•
•
•
•
•

Childhood onset
Diplegic cerebral palsy
Structural (Chiari
malformation, atlanto-axial
subluxation)
Leucodystrophy (eg, Krabbe’s)
Metabolic (arginase defi
ciency, abetalipoproteinaemia)
Levodopa-responsive dystonia
Infection (myelitis)
Multiple sclerosis

•
•
•
•

•
•
•
•
•
•
•
•
•
•
•

Adult onset
Cervical spine degenerative
disease
Multiple sclerosis
Motor neuron disease
Neoplasm (primary/secondary
spinal tumour, parasagittal
meningioma)
Infection (myelitis)
Dural arteriovenous malformation
Chiari malformation
Adrenoleucodystrophy
Hereditary spastic paraplegia
Spinocerebellar ataxias
Vitamin defi ciency (B12 and E)
Lathyrism
Levodopa-responsive dystonia
Infection (syphilis, human T-cell
leukaemia virus 1, HIV)
Copper deficiency
Treatment
No specific treatment is known that
would prevent, slow, or reverse HSP
Available therapies mainly consist
of symptomatic medical management
and promoting physical and emotional
well-being
Gen.
Spas
ticity
Oral
Agents

Foc.
Spas
ticity

Reg.
Spas
ticity

Botulinum
Toxins.Ph
enol
Blockade

IntraThecal
Baclofen
•

Baclofen– a voluntary muscle relaxant to relax muscles and
reduce tone

• Tizanidine – to treat nocturnal or intermittent spasms
• Diazepam and Clonazepam – to decrease intensity of spasms
• Oxybutynin chloride– an involuntary muscle relaxant and
spasmolytic agent, used to reduce spasticity of the bladder in
patients with bladder control problems

• Tolterodine tartate – an involuntary muscle relaxant and
spasmolytic agent, used to reduce spasticity of the bladder in
patients with bladder control problems

• Botulinu toxin – to reduce muscle overactivity
• Antidepressants (such as selective serotonin re-uptake
inhibitors, tricyclic antidepressants and monoamine oxidase
inhibitors) – for patients experiencing clinical depression
Physical Therapy
 To restore and maintain the ability to move
 To reduce muscle tone
 To maintain or improve range of motion and
mobility
 To increase strength and coordination
 To prevent complications, such as frozen
joints, contractures, or bedsores.
Hereditary spastic paraplegia
Hereditary spastic paraplegia

Hereditary spastic paraplegia

  • 2.
  • 3.
    Definition: is a groupof inherited diseases whose main feature is progressive stiffness and contraction (spasticity) in the lower limbs , as a result of damage to or dysfunction of the nerves.
  • 4.
    1-10 in 100,000people worldwide have HSP  Can affect people of all ages , but average age at onset is 24
  • 5.
    1 2 3 4 • Hereditary spasticparesis • Familial spastic paraplegia • Strumpell-Lorrain disease: first described 1883-1888 • French Settlement
  • 7.
    Based on symptoms Pure HSP    Affects thelegs only More common Bladder symptoms may occur eg “urgency” Complicated HSP  Spastic paraplegia with a variety of other problems  Other neurological problems eg ataxia (poor balance) Intellectual disability , dementia, extrapyramidal signs,Seizures
  • 8.
  • 9.
  • 10.
    Based on patient's age atonset Type I <35 years Type II >35 years Spasticity>>weakness muscle weakness urinary symptoms sensory loss spasticity
  • 11.
    Based on associatedgene (Genetics)  Neuronal degeneration mutations at specific genes  Genetic mapping has identified at least 52 different HSP loci, designated SPG 1 through 52  Different genetic types of HSP usually cannot be distinguished by clinical and neuroimaging parameters alone
  • 12.
    SPG1 (Spastic Paraplegia1)  Masa syndrome Gareis-Mason syndrome Crash syndrome  Mutation in Gene >>>>> L1 or L1CAM protein  Transmembrane protein >>>> neurite outgrowth guidance, neuronal cell migration and survival  Locus = Xq28 X-Linked
  • 13.
    SPG2  Mutation inGene >>>>> Proteolipid protein 1(PLP1)  Transmembrane protein >>>> leukodystrophy and dysmyelination, resulting in axonal degeneration  Locus = Xq22 X-Linked
  • 14.
    SPG4  Mutation inGene SPAST >>>>> Spastin protein  Microtubule-severing protein >>> membrane trafficking, intracellular motility, organelle biogenesis, protein folding, and proteolysis  Locus = 2p22–p21 Autosomal dominant
  • 15.
    SPG15  Kjellin syndrome Mutation in Gene >>>>> ZFYVE26  progressive stiffness and increased reflexes in the leg muscles as well as retinal degeneration  Locus =14q24.1 Autosomal recessive
  • 16.
    SPG17  Silver syndrome Mutation in Gene BSCL2 >>>>> Seipin protein  Phenotype overlapping with distal spinal muscular atrophy type VA  Locus = 11q13 Autosomal dominant
  • 17.
    SPG18  Mutation inGene >>>>> Erlin-2  Characterised by joint contractures and intellectual disability  Locus = 8p11.23 Autosomalrecessive
  • 18.
  • 19.
  • 21.
  • 23.
    Clinical Features  Symptomsdepend on the type of HSP inherited  Main feature >>> progressive spasticity in the lower limbs, due to pyramidal tract dysfunction  In the lower extremities, spasticity is increased at the hamstrings, quadriceps and ankles  Weakness is most notable at the iliopsoas , tibialis anterior, hamstring muscles  difficulty in walking, decreased vibratory sense at the ankles, and paresthesia  In lower extremities hyperreflexia, brisk reflexes, extensor plantar reflexes
  • 24.
    Normal reflex duringwalking Abnormal reflex during Gait/walking
  • 25.
     additional symptomsin complicated form include: peripheral neuropathy, amyotrophy, ata xia, mentalretardation, ichthyosis, epile psy,optic neuropathy, dementia, deafne ss, or problems with speech, swallowing or breathing
  • 26.
    Diagnosis Genetic Instrumental testing Tests Examination leg musclesBrain and spine MRI Family feel stiff Rule out other history causes brisk reflexes any History relatives Complains affected? eg .walking difficulty
  • 27.
    Genetic testing • Diagnostic -Person is affected with symptoms - Wants to know the cause • Predictive - Person not affected with symptoms - Has a relative eg parent with HSP
  • 28.
    Differential Diagnosis • • • • • • • Childhood onset Diplegiccerebral palsy Structural (Chiari malformation, atlanto-axial subluxation) Leucodystrophy (eg, Krabbe’s) Metabolic (arginase defi ciency, abetalipoproteinaemia) Levodopa-responsive dystonia Infection (myelitis) Multiple sclerosis • • • • • • • • • • • • • • • Adult onset Cervical spine degenerative disease Multiple sclerosis Motor neuron disease Neoplasm (primary/secondary spinal tumour, parasagittal meningioma) Infection (myelitis) Dural arteriovenous malformation Chiari malformation Adrenoleucodystrophy Hereditary spastic paraplegia Spinocerebellar ataxias Vitamin defi ciency (B12 and E) Lathyrism Levodopa-responsive dystonia Infection (syphilis, human T-cell leukaemia virus 1, HIV) Copper deficiency
  • 29.
    Treatment No specific treatmentis known that would prevent, slow, or reverse HSP Available therapies mainly consist of symptomatic medical management and promoting physical and emotional well-being
  • 30.
  • 31.
    • Baclofen– a voluntarymuscle relaxant to relax muscles and reduce tone • Tizanidine – to treat nocturnal or intermittent spasms • Diazepam and Clonazepam – to decrease intensity of spasms • Oxybutynin chloride– an involuntary muscle relaxant and spasmolytic agent, used to reduce spasticity of the bladder in patients with bladder control problems • Tolterodine tartate – an involuntary muscle relaxant and spasmolytic agent, used to reduce spasticity of the bladder in patients with bladder control problems • Botulinu toxin – to reduce muscle overactivity • Antidepressants (such as selective serotonin re-uptake inhibitors, tricyclic antidepressants and monoamine oxidase inhibitors) – for patients experiencing clinical depression
  • 32.
    Physical Therapy  Torestore and maintain the ability to move  To reduce muscle tone  To maintain or improve range of motion and mobility  To increase strength and coordination  To prevent complications, such as frozen joints, contractures, or bedsores.